Filing search / scPharmaceuticals Inc. / "Innovative"

8-K

EX-99.1

SCPH scPharmaceuticals Inc.

10 Jan 25

Results of Operations and Financial Condition

8:01am

are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments

8-K

EX-99.1

SCPH scPharmaceuticals Inc.

13 Nov 24

Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients

4:40pm

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments

8-K

EX-99.1

SCPH scPharmaceuticals Inc.

14 Aug 24

Completed financing that extends our cash runway through expected profitability

4:01pm

, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus

8-K

EX-99.1

SCPH scPharmaceuticals Inc.

14 May 24

Results of Operations and Financial Condition

4:07pm

, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead program focuses

8-K

EX-99.1

y8m0 v5qap

13 Mar 24

Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January

4:08pm

8-K

EX-99.1

qkgsajrjgqo8c5lgrj

4 Jan 24

Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4

5:30pm

8-K

EX-99.1

fcu17f

8 Nov 23

Results of Operations and Financial Condition

4:05pm

8-K

EX-99.1

0tipawk6z6y2s71ov3

10 Aug 23

Results of Operations and Financial Condition

4:05pm

8-K

EX-99.1

rw2sv511p4i vlia7azy

10 May 23

Announced launch and commercial availability of FUROSCIX® on February 20th

4:08pm

8-K

EX-99.1

1hx33 qb4ts

9 Nov 22

Entered into a secured debt financing agreement for up to $100 million with funds managed by Oaktree

4:07pm

8-K

EX-99.1

z19w5jq kd64fncss0q

9 Aug 22

Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act

7:14am

8-K

EX-99.1

sqd64b

12 Jul 22

Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpoints

8:08am

8-K

EX-99.1

1z9s2i9 t2q4vubxegos

16 May 22

Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved

7:26am

8-K

EX-99.1

sqgfdded 6j23u3zith

16 May 22

Company preparing for Q4 commercial launch, if approved

7:14am

8-K

EX-99.1

n4chy9 vw0

11 Apr 22

Anticipates Q4 2022 commercial launch, if approved

7:44pm

8-K

EX-99.1

w2zh5v4qm9h50s

22 Mar 22

Commercial preparedness activities ramping up to support anticipated Q4 2022 launch of FUROSCIX, if approved

7:11am

8-K

EX-99.1

9pwlirsi

9 Nov 21

All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date

7:09am

8-K

EX-99.1

jnb 7npnepqzwl

10 Sep 21

Heart Failure Society of America Annual Scientific Meeting 2021

8:12am